Investigation of ocular neovascularization-related genes and oxidative stress in diabetic rat eye tissues after resveratrol treatment

Journal of Medicinal Food

Volumn 15, Issue 4, 2012, Pages 391-398

  Yar, Atiye Seda ^a   Menevse, Sevda ^a   Dogan, Irem ^a   Alp, Ebru ^a   Ergin, Volkan ^a   Cumaoglu, Ahmet ^a   Aricioglu, Aysel ^a   Ekmekci, Abdullah ^a   Menevse, Adnan ^a  

^a GAZI UNIVERSITY   (Turkey)

Author keywords

diabetes mellitus; ocular neovascularization; oxidative stress; resveratrol

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GELATINASE B; GLUTATHIONE; MESSENGER RNA; NITRATE; NITRITE; RESVERATROL; VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DIABETIC RETINOPATHY; GENE; GENE EXPRESSION PROFILING; MALE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; OCULAR NEOVASCULARIZATION; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN CARBONYLATION; PROTEIN CONTENT; QUANTITATIVE ANALYSIS; RAT; REAL TIME POLYMERASE CHAIN REACTION; SPECTROPHOTOMETRY; STREPTOZOCIN DIABETES; TISSUE HOMOGENATE;

ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC RETINOPATHY; EYE; MALE; MATRIX METALLOPROTEINASE 9; NEOVASCULARIZATION, PATHOLOGIC; NITRATES; NITRIC OXIDE SYNTHASE TYPE III; NITRITES; OXIDATIVE STRESS; PEPTIDYL-DIPEPTIDASE A; RATS; RATS, WISTAR; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER; STILBENES; STREPTOZOCIN; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

RATTUS; RICE STRIPE VIRUS;

EID: 84859092595     PISSN: 1096620X     EISSN: 15577600     Source Type: Journal    
DOI: 10.1089/jmf.2011.0135     Document Type: Article

References (65)

1. Henkind P: Ocular neovascularization. The Krill Memorial Lecture. Am J Ophthalmol 1978;85:287-301.
2. Takagi H: Molecular mechanisms of retinal neovascularization in diabetic retinopathy. Intern Med 2003;42:299-301.
3. Grabowski WM, Brown GC, Cruess A: Peripheral retinal neovascularization in diabetes mellitus. Int Ophthalmol 1985;8:43-46.
4. Ferris FL: A new treatment for ocular neovascularization. N Engl J Med 2004;351:2863-2865.
5. Crawford TN, Alfaro DV 3rd, Kerrison JB, Jablon EP: Diabetic retinopathy and angiogenesis. Curr Diabetes Rev 2009;5:8-13.
6. Grant MB, Afzal A, Spoerri P, Pan H, Shaw LC, Mames RN: The role of growth factors in the pathogenesis of diabetic retinopathy. Expert Opin Investig Drugs 2004;13:1275-1293.
7. Miller JW, Adamis AP, Aiello LP: Vascular endothelial growth factor in ocular neovascularization and proliferative diabetic retinopathy. Diabetes Metab Rev 1997;13:37-50.
8. Sone H, Kawakami Y, Okuda Y, et al.: Ocular vascular endothelial growth factor levels in diabetic rats are elevated before observable retinal proliferative changes. Diabetologia 1997;40: 726-730.
9. Gerhardinger C, Brown LF, Roy S, Mizutani M, Zucker CL, Lorenzi M: Expression of vascular endothelial growth factor in the human retina and in nonproliferative diabetic retinopathy. Am J Pathol 1998;152:1453-1462.
10. Sjolie AK, Chaturvedi N: The retinal renin-angiotensin system: implications for therapy in diabetic retinopathy. J Hum Hypertens 2002;16:42-46.
11. Deinum J, Chaturvedi N: The renin-angiotensin system and vascular disease in diabetes. Semin Vasc Med 2002;2:149-156.
12. Zheng Z, Chen H, Xu X, Li C, Gu Q: Effects of angiotensinconverting enzyme inhibitors and beta-adrenergic blockers on retinal vascular endothelial growth factor expression in rat diabetic retinopathy. Exp Eye Res 2007;84:745-752.
13. Moravski CJ, Kelly DJ, Cooper ME, et al.: Retinal neovascularization is prevented by blockade of the renin-angiotensin system. Hypertension 2000;36:1099-1104.
14. Massova I, Kotra LP, Fridman R, Mobashery S: Matrix metalloproteinases: structures, evolution, and diversification FASEB J 1998;12:1075-1095.
15. Uemura S, Matsushita H, Li W, et al.: Diabetes mellitus enhances vascular matrix metalloproteinase activity. Role of oxidative stress. Circ Res 2001;88:1291-1298.
16. Campochiaro PA: Gene therapy for ocular neovascularization. Curr Gene Ther 2007;7:25-33.
17. Sheng H, Ignarro LJ: Biochemical and immunohistochemical characterization of nitric oxide synthase in the rat retina. Pharmacol Res 1996;33:29-34.
18. Goldstein IM, Ostwald P, Roth S: Nitric oxide: a review of its role in retinal function and disease. Vision Res 1996;36:2979-2994.
19. Papapetropoulos A, Garcia-Cardena G, Madri JA, Sessa WC: Nitric oxide production contributes to the angiogenic properties of vascular endothelial growth factor in human endothelial cells. J Clin Invest 1997;100:3131-3139.
20. Parenti A, Morbidelli L, Cui XL, et al.: Nitric oxide is an upstream signal of vascular endothelial growth factor-induced extracellular signal regulated kinase 1/2 activation in postcapillary endothelium. J Biol Chem 1998;273:4220-4226.
21. Beckman JS, Beckman TW, Chen J, Marshall PA, Freeman BA: Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. Proc Natl Acad Sci USA 1990;87:1620-1624.
22. Pryor WA, Squadrito GL: The chemistry of peroxynitrite: a product from the reaction of nitric oxide with superoxide. Am J Physiol 1995;268:699-722.
23. Beckman JS: Oxidative damage and tyrosine nitration from peroxynitrite. Chem Res Toxicol 1996;9:836-844.
24. Vincent AM, Russell JW, Low P, Feldman EL: Oxidative stress in the pathogenesis of diabetic neuropathy. Endocr Rev 2004;25: 612-628.
25. Rema M, Mohan V, Bhaskar A, Shanmugasundaram KR: Does oxidant stress play a role in diabetic retinopathy? Indian J Ophthalmol 1995;43:17-21.
26. Telci A, Cakatay U, Salman S, Satman I, Sivas A: Oxidative protein damage in early stage type 1 diabetic patients. Diabetes Res Clin Pract 2000;50:213-223.
27. Dong A, Xie B, Shen J, et al.: Oxidative stress promotes ocular neovascularization. J Cell Physiol 2009;219:544-552.
28. Bertelli AA, Giovannini L, Bernini W, et al.: Antiplatelet activity of cis-resveratrol. Drugs Exp Clin Res 1996;22:61-63.
29. Frémont L: Biological effects of resveratrol. Life Sci 2000; 66:663-673.
30. Kaga S, Zhan L, Matsumoto M, Maulik N: Resveratrol enhances neovascularization in the infarcted rat myocardium through the induction of thioredoxin-1, heme oxygenase 1 and vascular endothelial growth factor. J Mol Cell Cardiol 2005;39:813-822.
31. Kim WT, Suh ES: Retinal protective effects of resveratrol via modulation of nitric oxide synthase on oxygen-induced retinopathy. Korean J Ophthalmol 2010;24:108-118.
32. Brakenhielm E, Cao R, Cao Y: Suppression of angiogenesis, tumor growth, and wound healing by resveratrol, a natural compound in red wine and grapes. FASEB J 2001;15:1798-1800.
33. Wallerath T, Deckert G, Ternes T, et al.: Resveratrol, a polyphenolic phytoalexin present in red wine, enhances expression and activity of endothelial nitric oxide synthase. Circulation 2002;106:1652-1658.
34. Gao D, Zhang X, Jiang X, et al.: Resveratrol reduces the elevated level of MMP-9 induced by cerebral ischemia-reperfusion in mice. Life Sci 2006;78:2564-2570.
35. Yar AS, Menevse S, Alp E, Helvacioglu F, Take G: The effects of resveratrol on cyclooxygenase-1 and cyclooxygenase-2 mRNA and protein levels in diabetic rat kidneys. Mol Biol Rep 2010;37:2323-2331.
36. Kumar A, Kaundal RK, Iyer S, Sharma SS: Effects of resveratrol on nevre functions, oxidative stress and DNA fragmentation in experimental diabetic neuropathy. Life Sci 2007;80: 1236-1244.
37. Ates O, Cayli SR, Yucel N, et al.: Central nervous system protection by resveratrol in streptozotocin-induced diabetic rats. J Clin Neurosci 2007;14:256-260.
38. Sedlak J, Lindsay RH: Estimation of total, protein-bound, and nonprotein sulfhydryl groups in tissue with Ellman's reagent. Anal Biochem 1968;25:192-205.
39. Levine RL, Garland D, Oliver CN, et al.: Determination of carbonyl content in oxidatively modified proteins. Methods Enzymol 1990;186:464-478.
40. Miranda KM, Espey MG, Wink DA: A rapid, simple spectrophotometric method for simultaneous detection of nitrate and nitrite. Nitric Oxide 2001;5:62-71.
41. Pfaffl MW, Horgan GW, Dempfle L: Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res 2002;30:e36.
42. Aiello LP: Angiogenic pathways in diabetic retinopathy. N Engl J Med 2005;353:839-841.
43. Aiello LP, Avery RL, Arrigg PG, et al.: Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994;331: 1480-1487.
44. Pierce EA, Avery RL, Foley ED, Aiello LP, Smith LE: Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization. Proc Natl Acad Sci USA 1995;92:905-909.
45. Losso JN, Truax RE, Richard G: trans-Resveratrol inhibits hyperglycemia- induced inflammation and connexin downregulation in retinal pigment epithelial cells. J Agric Food Chem 2010; 58:8246-8252.
46. Qaum T, Xu Q, Joussen AM, et al.: VEGF-initiated blood-retinal barrier breakdown in early diabetes. Invest Ophthalmol Vis Sci 2001;42:2408-2413.
47. Fischer S, Clauss M, Wiesnet M, Renz D, Schaper W, Karliczek GF: Hypoxia induces permeability in brain microvessel endothelial cells via VEGF and NO. Am J Physiol 1999;276:812-820.
48. Ku DD, Zaleski JK, Liu S, Brock TA: Vascular endothelial growth factor induces EDRF-dependent relaxation in coronary arteries. Am J Physiol 1993;265:586-592.
49. Moncada S, Palmer RM, Higgs EA: Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 1991;43:109-142.
50. Duda DG, Fukumura D, Jain RK: Role of eNOS in neovascularization: NO for endothelial progenitor cells. Trends Mol Med 2004;10:143-145.
51. Ando A, Yang A, Nambu H, Campochiaro PA: Blockade of nitric-oxide synthase reduces choroidal neovascularization. Mol Pharmacol 2002;62:539-544.
52. Nagai N, Oike Y, Izumi-Nagai K, et al.: Suppression of choroidal neovascularization by inhibiting angiotensin-converting enzyme: minimal role of bradykinin. Invest Ophthalmol Vis Sci 2007;48: 2321-2326.
53. Melzig MF, Escher F: Induction of neutral endopeptidase and angiotensin-converting enzyme activity of SK-N-SH cells in vitro by quercetin and resveratrol. Pharmazie 2002;57:556-558.
54. Olszanecki R, Bujak-Gizycka B, Madej J, et al.: Kaempferol, but not resveratrol inhibits angiotensin converting enzyme. J Physiol Pharmacol 2008;59:387-392.
55. Saijonmaa O, Nyman T, Kosonen R, Fyhrquist F: Upregulation of angiotensin-converting enzyme by vascular endothelial growth factor. Am J Physiol Heart Circ Physiol 2001;280:885-891.
56. Moravski CJ, Kelly DJ, Cooper ME, et al.: Retinal neovascularization is prevented by blockade of the renin-angiotensin system. Hypertension 2000;36:1099-1104.
57. Higgins RD, Yan Y, Geng Y, Sharma J, Barr SM: Captopril and vascular endothelial growth factor in a mouse model of retinopathy. Curr Eye Res 2003;27:123-129.
58. Gilbert RE, Kelly DJ, Cox AJ, et al.: Angiotensin converting enzyme inhibition reduces retinal overexpression of vascular endothelial growth factor and hyperpermeability in experimental diabetes. Diabetologia 2000;43:1360-1367.
59. Aydin E, Demir HD, Sahin S: Plasma and aqueous humor angiotensin- converting enzyme levels in patients with diabetic retinopathy. Curr Eye Res 2010;35:230-234.
60. Ishizaki E, Takai S, Ueki M, et al.: Correlation between angiotensin-converting enzyme, vascular endothelial growth factor, and matrix metalloproteinase-9 in the vitreous of eyes with diabetic retinopathy. Am J Ophthalmol 2006;141:129-134.
61. Jin M, Kashiwagi K, Iizuka Y, Tanaka Y, Imai M, Tsukahara S: Matrix metalloproteinases in human diabetic and nondiabetic vitreous. Retina 2001;21:28-33.
62. Salzmann J, Limb GA, Khaw PT, et al.: Matrix metalloproteinases and their natural inhibitors in fibrovascular membranes of proliferative diabetic retinopathy. Br J Ophthalmol 2000;84: 1091-1096.
63. Higa A, Nakanishi-Ueda T, Arai Y, et al.: Lipid hydroperoxide induced corneal neovascularization in hyperglycemic rabbits. Curr Eye Res 2002;25:49-53.
64. Hoffmann S, Friedrichs U, Eichler W, Rosenthal A, Wiedemann P: Advanced glycation end products induce choroidal endothelial cell proliferation, matrix metalloproteinase-2 and VEGF upregulation in vitro. Graefes Arch Clin Exp Ophthalmol 2002; 240:996-1002.
65. Okamoto T, Tanaka S, Stan AC, et al.: Advanced glycation end products induce angiogenesis in vivo. Microvasc Res 2002;63: 186-195.